Boswellic Acids And Their Role In Chronic Inflammatory Diseases.
Published 2016 · Medicine, Biology
Download PDFAnalyze on Scholarcy
Boswellic acids, which are pentacyclic triterpenes belong to the active pharmacological compounds of the oleogum resin of different Boswellia species. In the resin, more than 12 different boswellic acids have been identified but only KBA and AKBA received significant pharmacological interest. Biological Activity: In an extract of the resin of Boswellia species multiple factors are responsible for the final outcome of a therapeutic effect, be it synergistic or antagonistic. Moreover, the anti-inflammatory actions of BAs are caused by different mechanisms of action. They include inhibition of leukotriene synthesis and to a less extend prostaglandin synthesis. Furthermore inhibition of the complement system at the level of conversion of C3 into C3a and C3b. A major target of BAs is the immune system. Here, BEs as well as BAs including KBA and AKBA, have been shown to decrease production of proinflammatory cytokines including IL-1, IL-2, IL-6, IFN-γ and TNF-α which finally are directed to destroy tissues such as cartilage, insulin producing cells, bronchial, intestinal and other tissues. NFĸB is considered to be the target of AKBA. The complex actions of BEs and BAs in inflamed areas may be completed by some effects that are localized behind the inflammatory process as such tissue destruction. In this case, in vitro- and animal studies have shown that BAs and BEs suppress proteolytic activity of cathepsin G, human leucocyte elastase, formation of oxygen radicals and lysosomal enzymes. PHARMACOKINETICS Whereas KBA is absorbed reaching blood levels being close to in vitro IC50, AKBA which is more active in in vitro studies than KBA, but undergoes much less absorption than KBA. However, absorption of both is increased more than twice when taken together with a high-fat meal.Clinical Studies There are a variety of chronic inflammatory diseases which respond to treatment with extracts from the resin of Boswellia species. Though, the number of cases is small in related clinical studies, their results are convincing and supported by the preclinical data. These studies include rheumatoid arthritis, osteoarthritis, chronic colitis, ulcerative colitis, collagenous colitis, Crohn's disease and bronchial asthma. It can not be expected that there is cure from these diseases but at least improvement of symptoms in about 60-70 % of the cases. Side Effects The number and severity of side effects is extremely low. The most reported complaints are gastrointestinal symptoms. Allergic reactions are rare. And most authors report, that treatment with BEs is well tolerated and the registered side effects in BE- and placebo groups are similar.
This paper references
Phytochemical screening and antiviral activity of some medicinal plants from the island Soqotra.
R. A. Mothana (2006)
Anti-inflammatory, antinociceptive and antioxidant activities of the endemic Soqotraen Boswellia elongata Balf. f. and Jatropha unicostata Balf. f. in different experimental models.
R. A. Mothana (2011)
Effects of gum resin of Boswellia serrata in patients with chronic colitis.
I. Gupta (2001)
Pharmacology of an extract of salai guggal ex-Boswellia serrata, a new non-steroidal anti-inflammatory agent
G. B. Singh (2005)
Inhibition by boswellic acids of human leukocyte elastase.
H. Safayhi (1997)
Acetyl‐11‐keto‐β‐boswellic acid (AKBA): structure requirements for binding and 5‐lipoxygenase inhibitory activity
E. Sailer (1996)
Prevention of multiple low-dose streptozotocin (MLD-STZ) diabetes in mice by an extract from gum resin of Boswellia serrata (BE).
A. M. Shehata (2011)
Randomized, placebo‐controlled, double‐blind trial of Boswellia serrata in maintaining remission of Crohn's disease: Good safety profile but lack of efficacy
W. Holtmeier (2011)
Comparative Efficacy and Tolerability of 5-Loxin® and Aflapin® Against Osteoarthritis of the Knee: A Double Blind, Randomized, Placebo Controlled Clinical Study
K. Sengupta (2010)
Analysis of pentacyclic triterpenic acids from frankincense gum resins and related phytopharmaceuticals by high-performance liquid chromatography. Identification of lupeolic acid, a novel pentacyclic triterpene.
B. Buechele (2003)
A novel C(28)-hydroxylated lupeolic acid suppresses the biosynthesis of eicosanoids through inhibition of cytosolic phospholipase A(2).
Moritz Verhoff (2012)
Acetyl-Boswellic Acids Inhibit Lipopolysaccharide-Mediated TNF-α Induction in Monocytes by Direct Interaction with IκB Kinases1
T. Syrovets (2005)
Boswellic Acids Stimulate Arachidonic Acid Release and 12-Lipoxygenase Activity in Human Platelets Independent of Ca2+ and Differentially Interact with Platelet-Type 12-Lipoxygenase
Daniel Poeckel (2006)
Ist H15 (Harzextrakt von Boswellia serrata, „Weihrauch“) eine sinnvolle Ergänzung zur etablierten medikamentösen Therapie der chronischen Polyarthritis? – Ergebnisse einer doppelblinden Pilotstudie
O. Sander (1998)
Immunomodulatory Activity of Boswellic Acids (Pentacyclic Triterpene Acids) fromBoswellia serrata
M. L. Sharma (1996)
A sensitive and relevant model for evaluating anti-inflammatory activity-papaya latex-induced rat paw inflammation.
O. P. Gupta (1992)
Extract from gum resin of Boswellia serrata decreases IA(2)-antibody in a patient with "Late onset Autoimmune Diabetes of the Adult" (LADA).
Ernst Schrott (2014)
Boswellia serrata Extrakt bei kollagener Kolitis-Eine randomisierte, placebo-kontrollierte, doppelblinde Multicenterstudie
A. Madisch (2005)
Synthesis of novel triterpenoid (lupeol) derivatives and their in vivo antihyperglycemic and antidyslipidemic activity.
K Papi Reddy (2009)
Boswellic acids: A leukotriene inhibitor also effective through topical application in inflammatory disorders.
S. Singh (2008)
Acetyl-11-Keto-β-Boswellic Acid Potentiates Apoptosis, Inhibits Invasion, and Abolishes Osteoclastogenesis by Suppressing NF-κB and NF-κB-Regulated Gene Expression1
Y. Takada (2006)
Boswellia carterii Extract Inhibits TH1 Cytokines and Promotes TH2 Cytokines In Vitro
M. R. Chevrier (2005)
Wirksamkeit und Unbedenklichkeit der H15 Ayurmedica-Therapie bei chronisch entzündlichen Erkrankungen
P. Buvari (2001)
Structural analysis of 3-α-acetyl-20(29)-lupene-24-oic acid, a novel pentacyclic triterpene isolated from the gum resin of Boswellia serrata, by NMR spectroscopy
K. Belsner (2003)
Permeation of Boswellia extract in the Caco-2 model and possible interactions of its constituents KBA and AKBA with OATP1B3 and MRP2.
Phillip Krüger (2009)
Special extract of BOSWELLIA serrata (H 15) in the treatment of rheumatoid arthritis.
R. Etzel (1996)
Effects of Boswellia serrata gum resin in patients with ulcerative colitis.
I. Gupta (1997)
Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee--a randomized double blind placebo controlled trial.
N. Kimmatkar (2003)
[Therapy of Crohn diseases--results of a Consensus Conference of the German Society of Digestive and Metabolic Diseases].
E. Stange (1997)
Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors
S. Kirste (2011)
Allergic contact dermatitis from Boswellia serrata extract in a naturopathic cream
E. Acebo (2004)
Screening of some Nigerian plants for molluscicidal activity.
S. L. Kela (1989)
Inhibitory effects of sudanese medicinal plant extracts on hepatitis C virus (HCV) protease.
G. Hussein (2000)
A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin® for treatment of osteoarthritis of the knee
K. Sengupta (2008)
Pure compound from Boswellia serrata extract exhibits anti-inflammatory property in human PBMCs and mouse macrophages through inhibition of TNFalpha, IL-1beta, NO and MAP kinases.
Balasubramaniam Gayathri (2007)
Chemical composition and antimicrobial activity of some oleogum resin essential oils from Boswellia spp. (Burseraceae).
L. Camarda (2007)
Analgesic effect of the gum resin of Boswellia serata Roxb.
A. Kar (1969)
Therapie des aktiven Morbus Crohn mit dem Boswellia-serrata-Extrakt H 15
H. Gerhardt (2001)
Open, randomized, controlled clinical trial of Boswellia serrata extract as compared to valdecoxib in osteoarthritis of knee
S. Sontakke (2007)
Antimicrobial activity of Boswellia dalziellii stem bark.
E. Adelakun (2001)
Discovery of cyclooxygenase inhibitors from medicinal plants used to treat inflammation.
Hongmei Cao (2010)
Inhibition of microsomal prostaglandin E2 synthase‐1 as a molecular basis for the anti‐inflammatory actions of boswellic acids from frankincense
U. Siemoneit (2011)
Identification of Human Cathepsin G As a Functional Target of Boswellic Acids from the Anti-Inflammatory Remedy Frankincense1
L. Tausch (2009)
Boswellia frereana (frankincense) suppresses cytokine-induced matrix metalloproteinase expression and production of pro-inflammatory molecules in articular cartilage.
E. Blain (2010)
Metabolism of Boswellic Acids in Vitro and in Vivo
P. Krueger (2008)
Identification and functional analysis of cyclooxygenase-1 as a molecular target of boswellic acids.
U. Siemoneit (2008)
Incensole Acetate, a Novel Anti-Inflammatory Compound Isolated from Boswellia Resin, Inhibits Nuclear Factor-κB Activation
A. Moussaieff (2007)
Acetyl-11-keto-β-boswellic acid (AKBA); targeting oral cavity pathogens
Alsaba F Raja (2011)
ALCOHOLIC EXTRACT OF SALAI-GUGGAL EX-BOSWELLIA SERRATA, A NEW NATURAL SOURCE NSAID
G. Singh (1996)
Immunological adjuvant effect of Boswellia serrata (BOS 2000) on specific antibody and cellular response to ovalbumin in mice.
A. Gupta (2011)
Analysis of 12 different pentacyclic triterpenic acids from frankincense in human plasma by high-performance liquid chromatography and photodiode array detection.
B. Buechele (2003)
Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities.
M. Cnop (2005)
Response of radiochemotherapy-associated cerebral edema to a phytotherapeutic agent, H15
J. Streffer (2001)
Chemistry and Immunomodulatory Activity of Frankincense Oil
Botros R Mikhaeil (2003)
Immunomodulatory activity of biopolymeric fraction BOS 2000 from Boswellia serrata.
A. Khajuria (2008)
Pharmacokinetic study of 11-Keto β-Boswellic Acid
S. Sharma (2004)
Anti-arthritic activity of boswellic acids in bovine serum albumin (BSA)-induced arthritis.
M. L. Sharma (1989)
Holy Saturday asthma
T. O'connor (2014)
Topical formulation of a new plant extract complex with refirming properties. Clinical and non‐invasive evaluation in a double‐blind trial
Antimicrobial activity of some medicinal plants of the island Soqotra.
R. A. Mothana (2005)
Leukotrienes as a Target in Asthma Therapy
N. Chanarin (2012)
Anticomplementary activity of boswellic acids--an inhibitor of C3-convertase of the classical complement pathway.
A. Kapil (1992)
Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study.
I. Gupta (1998)
Boswellia serrata extract attenuates inflammatory mediators and oxidative stress in collagen induced arthritis.
S. Umar (2014)
Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-beta-boswellic acid.
H. Safayhi (1995)
Effect of food intake on the bioavailability of boswellic acids from a herbal preparation in healthy volunteers.
V. Sterk (2004)
On the interference of boswellic acids with 5-lipoxygenase: mechanistic studies in vitro and pharmacological relevance.
U. Siemoneit (2009)
Effects of an acetone extract of Boswellia carterii Birdw. (Burseraceae) gum resin on rats with persistent inflammation.
A. Fan (2005)
In vitro anti-biofilm activity of Boswellia spp. oleogum resin essential oils.
D. Schillaci (2008)
Characterization of an acetyl-11-keto-beta-boswellic acid and arachidonate-binding regulatory site of 5-lipoxygenase using photoaffinity labeling.
E. Sailer (1998)
Antiinflammatory and Antiatherogenic Effects of the NF-&kgr;B Inhibitor Acetyl-11-Keto-β-Boswellic Acid in LPS-Challenged ApoE−/− Mice
C. Cuaz-Pérolin (2007)
Inhibition of leukotriene B4 formation in rat peritoneal neutrophils by an ethanolic extract of the gum resin exudate of Boswellia serrata.
H. Ammon (1991)
Targeting NF-κB with a Natural Triterpenoid Alleviates Skin Inflammation in a Mouse Model of Psoriasis1
H. Wang (2009)
11-Keto-β-Boswellic Acids Prevent Development of Autoimmune Reactions, Insulitis and Reduce Hyperglycemia During Induction of Multiple Low-Dose Streptozotocin (MLD-STZ) Diabetes in Mice.
Ahmed M Shehata (2015)
Complete structural assignment of serratol, a cembrane-type diterpene from Boswellia serrata, and evaluation of its antiprotozoal activity.
Thomas Jürgen Schmidt (2011)
Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase.
H. Safayhi (1992)
[Therapy of Crohn's disease].
H. Malchow (1984)
This paper is referenced by
Boswellic extracts and 11-keto-ß-boswellic acids prevent type 1 and type 2 diabetes mellitus by suppressing the expression of proinflammatory cytokines.
Hermann P. T. Ammon (2019)
Phytochemicals as modulators of β-cells and immunity for the therapy of type 1 diabetes: Recent discoveries in pharmacological mechanisms and clinical potential.
Maria Karmella Apaya (2020)
A Systematic Review on Frankincense (Boswellia species)
Swati Yadav (2018)
Functional improvement and immune-inflammatory cytokines profile of ischaemic stroke patients after treatment with boswellic acids: a randomized, double-blind, placebo-controlled, pilot trial
Somayeh Mahmoodi Baram (2019)
Defined Structure-Activity Relationships of Boswellic Acids Determine Modulation of Ca2+ Mobilization and Aggregation of Human Platelets by Boswellia serrata Extracts.
Ulf Siemoneit (2017)
Boswelliaextrakte/Boswelliasäuren bei malignen Tumoren: Eine Übersicht
Hpt Ammon (2019)
Targeting cytokines in the 5-Lox pro-inflammatory pathway for treatment-resistant anorexia nervosa
Samantha Jane Brooks (2018)
Role of Jumpstart Nutrition®, a Dietary Supplement, to Ameliorate Calcium-to-Phosphorus Ratio and Parathyroid Hormone of Patients with Osteoarthritis
Apurba Ganguly (2019)
A review of the therapeutic effects of frankincense
Soheila Noroozi (2018)
A Brief Review of Nutraceutical Ingredients in Gastrointestinal Disorders: Evidence and Suggestions
Xiang Gao (2020)
Terpenoids as Potential Geroprotectors
Ekaterina Proshkina (2020)
Evidenz und Tradition am Beispiel der Phytopharmaka
R. Juette (2017)
Estimation of boswellic acids in herbal formulations containing Boswellia serrata extract and comprehensive characterization of secondary metabolites using UPLC-Q-Tof-MSe
Kumar Katragunta (2019)
Repeat oral dose safety study of standardized methanolic extract of Boswellia sacra oleo gum resin in rats
Abdulrahman A. I. AL-Yahya (2020)
Genus Boswellia as a new candidate for neurodegenerative disorders
Arezoo Rajabian (2020)
Current status of top 10 nutraceuticals used for Knee Osteoarthritis in India.
Raju Vaishya (2018)
Anti-Inflammatory Activity of Boswellia serrata Extracts: An In Vitro Study on Porcine Aortic Endothelial Cells
Martina Bertocchi (2018)
Nutraceuticals and osteoarthritis pain
Angela A. Wang (2018)
Toxicological Assessment of a Standardized Boswellia serrata Gum Resin Extract
Venkata Krishnaraju Alluri (2019)
Herbal medicinal products for inflammatory bowel disease: A focus on those assessed in double-blind randomised controlled trials.
G. Holleran (2019)
Comparative Investigation of Frankincense Nutraceuticals: Correlation of Boswellic and Lupeolic Acid Contents with Cytokine Release Inhibition and Toxicity against Triple-Negative Breast Cancer Cells
Michael Schmiech (2019)
Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities.
Thomas Efferth (2020)
A pilot, randomized, double‐blind, placebo‐controlled trial to assess the safety and efficacy of a novel Boswellia serrata extract in the management of osteoarthritis of the knee
M. Majeed (2019)
Improvement of Human-Oral-Epithelial-Barrier Function and of Tight Junctions by Micronutrients.
E. Rybakovsky (2017)
The major Boswellia serrata active 3-acetyl-11-keto-β-boswellic acid strengthens interleukin-1α upregulation of matrix metalloproteinase-9 via JNK MAP kinase activation.
Elia Ranzato (2017)
Googling the Guggul (Commiphora and Boswellia) for Prevention of Chronic Diseases
Ajaikumar B. Kunnumakkara (2018)
3-acetyl-11-keto-beta-boswellic acid decreases the malignancy of taxol resistant human ovarian cancer by inhibiting multidrug resistance (MDR) proteins function.
Lu Jin (2019)
Enhanced absorption of boswellic acids by a micellar solubilized delivery form of Boswellia extract
Juergen Meins (2018)
3-O-acetyl-11-keto-β-boswellic acid exerts anti-tumor effects in glioblastoma by arresting cell cycle at G2/M phase
W. Li (2018)
An Update on Pharmacological Potential of Boswellic Acids against Chronic Diseases
Nand Kishor Roy (2019)
Acetyl-11-keto-β-boswellic acid enhances the cisplatin sensitivity of non-small cell lung cancer cells through cell cycle arrest, apoptosis induction, and autophagy suppression via p21-dependent signaling pathway
Minghe Lv (2020)
Acetyl-11-keto-β-boswellic acid attenuates titanium particle-induced osteogenic inhibition via activation of the GSK-3β/β-catenin signaling pathway
Longbin Xiong (2019)See more